MAP2K7 and rhabdomyosarcoma: In our previous studies, we evaluated the efficacy of the combination of the MEK inhibitor, trametinib, with a monoclonal antibody specific for IGF1R, ganitumab, in RAS-mutated rhabdomyosarcoma [52].